Ovarian Cancer Clinical Trials

Showing 321-340 of 574 trials

Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

NCT04295577

This is a multi-centre, observational (non-interventional) study, designed to follow patients with advanced ovarian fallopian tube and primary peritoneal cancer, who are receiving Niraparib as maintenance treatment, according to the Niraparib access criteria (via TESARO patient access programme, EMA licence and NHS pending NICE assessment due 2018) including assessment of tolerability to Niraparib therapy.

Ovarian CancerPeritoneal CancerFallopian Tube Cancer

Royal Marsden NHS Foundation Trust350 participantsStarted Feb 2020

Bath, United Kingdom • Belfast, United Kingdom • Birmingham, United Kingdom +12 more locations

COMPLETED

Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

NCT05188781

Primary: To evaluate improvement in progression-free survival for patients treated with anti-PD1 pembrolizumab in combination with Anlotinib as compared to pembrolizumab single treated Secondary: To obtain pilot data on clinical response rates using both RECIST1.1 criteria (Response Evaluation Criteria in Solid Tumors) and immune related response criteria (irRECIST). Objectives • To obtain data on changes in tumor microenvironment prior to and subsequent to therapy and, to screen for potential biomarkers to predict clinical benefit combination in the study population. * To assess the impact of the combination of anlotinib and pembrolizumab * To determine the safety and tolerability of the treatment of anlotinib and pembrolizumab * To evaluate overall survival in patients treated with anti-PD-1 pembrolizumab and anlotinib

High-Grade Serous Ovarian Cancer

The Affiliated Hospital of Qingdao University34 participantsStarted Jan 2019

Qingdao, Shandong, China

Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

Related Searches

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib

Feasibility of a New Technology for Isolating Circulating Tumour Cells

Statewide Communication to Reach Diverse Low Income Women

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients

Study of Predictive Factors of Chemoresistance in Ovarian Cancer

Analyzing the Composition of Tears to Identify Cancer

Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging

Decision Support for BRCA Testing in Ethnically Diverse Women

Study of DP303c Injection in Patients With Advanced Ovarian Cancer